Ying Liang1,2, Drolma Yangzom2, Lhamo Tsokyi2, Yanping Ning2, Baiyan Su3,4, Shuai Luo4, Bian Ma Cuo2, Meilang ChuTso2, Yanling Ding1, Yahong Chen1, Yongchang Sun1. 1. Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China. 2. Department of Respiratory and Critical Care Medicine, Tibet Autonomous Region People's Hospital, Lhasa, 850000, People's Republic of China. 3. Radiology Department, Peking Union Medical College Hospital, Beijing, 100730, People's Republic of China. 4. Radiology Department, Tibet Autonomous Region People's Hospital, Lhasa, 850000, People's Republic of China.
Abstract
Background: COPD at high altitude may have different risk factors and unique clinical and radiological phenotypes. We aimed to investigate the demographic data, clinical and radiological features of COPD patients permanently residing at the Tibet Plateau (≥3000 meters above sea level). Methods: We conducted an observational cross-sectional study which consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to March 2021. All patients were Tibetan permanent residents aging ≥40 years and met the diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Data including demographic characteristics, altitude of residence, risk factors, respiratory symptoms, comorbidities and medications, as well as computed tomography (CT) measurements were collected. Results: Eighty-four patients with definite COPD were enrolled for analysis. Their mean age was 64.7 (±9.1) years. All patients lived at ≥3000 m above sea level and 34.5% of them lived at ≥4000 m. About 8.3% of the patients were current smokers and 44.0% were ex-smokers. Up to 88.1% of the patients reported long-term exposure to indoor biomass fuels. Most of the patients were classified as having mild-to-moderate (GOLD I: 27.4%; GOLD II: 51.2%) COPD, while 89.3% had a CAT score ≥10. Only 36.9% of the patients received regular long-term medications for COPD in the past year, in whom ICS/LABA and oral theophylline were the most common used pharmacological therapy. On CT scanning, the majority of our patients (70.7%) showed no or minimal emphysema, while signs of previous tuberculosis were found in 45.1% of the patients. Conclusion: COPD patients living at the Tibet Plateau had a heavy respiratory symptom burden, but most of them did not receive adequate pharmacological treatment. Indoor biomass fuel exposure and previous tuberculosis were prevalent, while the emphysema phenotype was less common in this population.
Background: COPD at high altitude may have different risk factors and unique clinical and radiological phenotypes. We aimed to investigate the demographic data, clinical and radiological features of COPD patients permanently residing at the Tibet Plateau (≥3000 meters above sea level). Methods: We conducted an observational cross-sectional study which consecutively enrolled COPD patients visiting the outpatient of Respiratory Medicine at Tibet Autonomous Region People's Hospital from January 2018 to March 2021. All patients were Tibetan permanent residents aging ≥40 years and met the diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. Data including demographic characteristics, altitude of residence, risk factors, respiratory symptoms, comorbidities and medications, as well as computed tomography (CT) measurements were collected. Results: Eighty-four patients with definite COPD were enrolled for analysis. Their mean age was 64.7 (±9.1) years. All patients lived at ≥3000 m above sea level and 34.5% of them lived at ≥4000 m. About 8.3% of the patients were current smokers and 44.0% were ex-smokers. Up to 88.1% of the patients reported long-term exposure to indoor biomass fuels. Most of the patients were classified as having mild-to-moderate (GOLD I: 27.4%; GOLD II: 51.2%) COPD, while 89.3% had a CAT score ≥10. Only 36.9% of the patients received regular long-term medications for COPD in the past year, in whom ICS/LABA and oral theophylline were the most common used pharmacological therapy. On CT scanning, the majority of our patients (70.7%) showed no or minimal emphysema, while signs of previous tuberculosis were found in 45.1% of the patients. Conclusion: COPD patients living at the Tibet Plateau had a heavy respiratory symptom burden, but most of them did not receive adequate pharmacological treatment. Indoor biomass fuel exposure and previous tuberculosis were prevalent, while the emphysema phenotype was less common in this population.
Authors: Amir Khakban; Don D Sin; J Mark FitzGerald; Raymond Ng; Zafar Zafarí; Bruce McManus; Zsuzsanna Hollander; Carlo A Marra; Mohsen Sadatsafavi Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Frederik van Gemert; Bruce Kirenga; Niels Chavannes; Moses Kamya; Simon Luzige; Patrick Musinguzi; John Turyagaruka; Rupert Jones; Ioanna Tsiligianni; Sian Williams; Corina de Jong; Thys van der Molen Journal: Lancet Glob Health Date: 2015-01 Impact factor: 26.763
Authors: Meilan K Han; Ella A Kazerooni; David A Lynch; Lyrica X Liu; Susan Murray; Jeffrey L Curtis; Gerard J Criner; Victor Kim; Russell P Bowler; Nicola A Hanania; Antonio R Anzueto; Barry J Make; John E Hokanson; James D Crapo; Edwin K Silverman; Fernando J Martinez; George R Washko Journal: Radiology Date: 2011-07-25 Impact factor: 11.105
Authors: Andreas Horner; Joan B Soriano; Milo A Puhan; Michael Studnicka; Bernhard Kaiser; Lowie E G W Vanfleteren; Louisa Gnatiuc; Peter Burney; Marc Miravitlles; Francisco García-Rio; Julio Ancochea; Ana M Menezes; Rogelio Perez-Padilla; Maria Montes de Oca; Carlos A Torres-Duque; Andres Caballero; Mauricio González-García; Sonia Buist; Maria Flamm; Bernd Lamprecht Journal: Respir Res Date: 2017-08-23
Authors: Mariaelena Occhipinti; Matteo Paoletti; James D Crapo; Barry J Make; David A Lynch; Vito Brusasco; Federico Lavorini; Edwin K Silverman; Elizabeth A Regan; Massimo Pistolesi Journal: Respir Res Date: 2020-05-01